Core Insights - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company is leveraging a proprietary data analytics platform to create a pipeline of oral tyrosine kinase 2 inhibitors and other therapies [2] - Upcoming investor conferences will feature Alumis, providing opportunities for engagement with investors [1][4] Company Overview - Alumis is developing therapies aimed at improving health outcomes for patients with immune-mediated diseases, including moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline includes envudeucitinib (formerly ESK-001) and A-005 for various systemic and neuroinflammatory conditions, as well as lonigutamab for thyroid eye disease [2] - The company has several preclinical programs identified through its precision approach [2] Upcoming Events - Alumis will participate in multiple investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 3 at 9:45 am ET [4] - Wells Fargo 2025 Healthcare Conference on September 5 at 9:30 am ET [4] - Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 4:50 pm ET [4] - H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 10:30 am ET [4] - Baird 2025 Global Healthcare Conference on September 10 at 2:35 pm ET [4] - Stifel 2025 Virtual Immunology & Inflammation Forum on September 16 at 12:30 pm ET [4]

Core Insights - Alumis Inc. has completed patient enrollment in pivotal clinical trials for its investigational therapy envudeucitinib, with topline data expected in early Q1 2026 for plaque psoriasis and Q3 2026 for systemic lupus erythematosus [1][2][5] - The company has successfully merged with ACELYRIN, Inc., enhancing its financial position and supporting the advancement of its late-stage immunology pipeline [1][2][7] - As of June 30, 2025, Alumis reported cash, cash equivalents, and marketable securities totaling $486.3 million, which is expected to fund operations into 2027 [1][10] Clinical Development - The Phase 3 ONWARD program for envudeucitinib includes two parallel global trials designed to evaluate its efficacy and safety in adult patients with moderate-to-severe plaque psoriasis, with topline data expected in early Q1 2026 [5][8] - The Phase 2b LUMUS trial for systemic lupus erythematosus has enrolled 408 patients, with topline data anticipated in Q3 2026 [5][8] Financial Performance - For the quarter ended June 30, 2025, Alumis reported total revenue of $2.7 million, primarily from collaboration revenue, compared to no revenue in the same quarter of 2024 [7][15] - Research and development expenses increased to $108.8 million for Q2 2025, up from $48.6 million in Q2 2024, driven by clinical trial costs and merger-related expenses [7][15] - The company recorded a net income of $59.3 million for Q2 2025, including a non-operating gain of $187.9 million from the merger with ACELYRIN, compared to a net loss of $56.5 million in Q2 2024 [7][15] Corporate Developments - The merger with ACELYRIN has strengthened Alumis' balance sheet, allowing for the advancement of its late-stage pipeline through multiple planned key data readouts [6][9] - The company has appointed Sanam Pangali as Chief Legal Officer and Corporate Secretary, bringing nearly two decades of legal expertise [6][8] Pipeline Updates - Alumis is advancing A-005, a fully CNS-penetrant TYK2 inhibitor, towards Phase 2 clinical trials for multiple sclerosis, expected to initiate in the first half of 2026 [8] - The company is also developing lonigutamab, a next-generation therapy for thyroid eye disease, which has received Fast Track Designation from the FDA [8][11]

Core Insights - Alumis Inc. has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor targeting systemic lupus erythematosus (SLE), with topline data expected in Q3 2026 [1][5]. Company Overview - Alumis is a late-stage biopharma company focused on developing targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform [7]. - The company is developing a pipeline of oral TYK2 inhibitors, including ESK-001 for SLE and moderate-to-severe plaque psoriasis, and A-005 for neuroinflammatory and neurodegenerative diseases [7]. Clinical Trial Details - The LUMUS Phase 2b trial is a randomized, double-blind, placebo-controlled study involving 408 patients with moderately-to-severely active, autoantibody-positive SLE, assessing the efficacy of ESK-001 over 48 weeks [2][5]. - The primary endpoint of the trial is to evaluate improvements in overall disease activity using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 48 [2][5]. Drug Mechanism and Efficacy - ESK-001 is designed to selectively target key inflammatory drivers, such as type 1 interferon (IFN), aiming for maximal inhibition while minimizing off-target effects [3][4]. - Clinical data from the psoriasis program indicates that ESK-001 downregulates key cytokines and disease biomarkers, suggesting potential to reduce SLE disease activity [4]. Future Prospects - The company anticipates that ESK-001 could provide biologic-like clinical responses for SLE, based on its performance in previous clinical studies [4].

Core Insights - Alumis Inc. has promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary, succeeding Sara Klein who has retired [1][2] - Sanam Pangali has a strong background in legal and business roles, previously serving as Senior Vice President, Legal at Alumis and holding leadership positions at ACELYRIN, Inc. and other biopharmaceutical companies [2] - Alumis is focused on developing next-generation targeted therapies for immune-mediated diseases, with a pipeline that includes oral tyrosine kinase 2 inhibitors and anti-insulin-like growth factor 1 receptor therapy [3] Company Overview - Alumis is a late-stage biopharma company dedicated to improving patient health outcomes in immune-mediated diseases [3] - The company utilizes a proprietary data analytics platform to develop its therapies, which include ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [3] - The pipeline also features lonigutamab for thyroid eye disease and several preclinical programs identified through a precision approach [3]

Company Overview - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [3] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [3] Pipeline Development - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including ESK-001 for systemic immune-mediated disorders like moderate-to-severe plaque psoriasis and systemic lupus erythematosus [3] - A-005 is being developed for neuroinflammatory and neurodegenerative diseases [3] - The pipeline also features lonigutamab, an anti-insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs [3] Upcoming Events - Martin Babler, President and CEO of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 3:10 p.m. ET [1] - A live webcast of the presentation will be available on the Alumis website, with a replay archived for 90 days [2]

Company Overview - Alumis Inc. has completed its merger with ACELYRIN, Inc., establishing itself as a leading clinical-stage biopharma company with a differentiated portfolio of therapies and a strong balance sheet [1][3] - Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, with ACELYRIN common stock ceasing to trade on NASDAQ [2] Financial Position - The merger significantly strengthens Alumis' balance sheet, allowing for the advancement of its late-stage portfolio and the development of transformative therapies for patients [3] - Alumis now has a cash runway that extends into 2027, supporting multiple planned key data readouts [3] Product Pipeline - Alumis is developing next-generation targeted therapies for immune-mediated diseases, including oral tyrosine kinase 2 inhibitors such as ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [5] - The pipeline also includes lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs identified through a precision approach [5] Advisory Team - Morgan Stanley & Co. LLC served as the financial advisor to Alumis, while Cooley LLP acted as its legal counsel [4] - Guggenheim Securities, LLC served as the financial advisor to ACELYRIN, with Fenwick & West LLP and Paul Hastings LLP providing legal counsel [4]

Core Viewpoint - ACELYRIN, Inc. has received stockholder approval for its merger with Alumis Inc., which is expected to enhance value through the combination of their complementary pipelines and organizations [1][2]. Group 1: Merger Details - The merger agreement stipulates that ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction [1]. - The transaction is anticipated to be completed in the second quarter of 2025 [3]. Group 2: Company Background - ACELYRIN, Inc. focuses on developing transformative medicines in immunology, with its lead program being lonigutamab, a monoclonal antibody for treating thyroid eye disease [5]. Group 3: Leadership Statements - The CEO of ACELYRIN expressed appreciation for stockholder support, indicating confidence in the merger as a value-maximizing strategy [2].

Core Viewpoint - ACELYRIN, INC. is urging its stockholders to vote in favor of the proposed merger with Alumis Inc., supported by a recommendation from Institutional Shareholder Services (ISS) [1][2]. Group 1: Proposed Transaction - The special meeting for stockholders to vote on the merger is scheduled for May 13, 2025 [2]. - ISS has recommended that stockholders vote "FOR" the merger, indicating it is the best path to maximize shareholder value [2][3]. - The merger is the result of a comprehensive process led by independent directors, aimed at creating a stronger, diversified company [2]. Group 2: Company Overview - ACELYRIN is a late-stage clinical biopharma company focused on developing transformative medicines in immunology [1][4]. - The company's lead program, lonigutamab, is a monoclonal antibody targeting IGF-1R for treating thyroid eye disease [4]. Group 3: Advisory and Legal Support - Guggenheim Securities, LLC is serving as the financial advisor for ACELYRIN, while Fenwick & West LLP and Paul Hastings LLP are providing legal counsel [3].

Core Viewpoint - The merger between Alumis Inc. and ACELYRIN, INC. has been amended to provide increased ownership for ACELYRIN stockholders, with the revised exchange ratio allowing Alumis stockholders to own approximately 52% and ACELYRIN stockholders to own approximately 48% of the combined company on a fully diluted basis, maximizing potential value for both parties [1][2]. Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases using a precision approach [10]. - ACELYRIN, INC. is a late-stage clinical biopharma company dedicated to accelerating the development and commercialization of transformative medicines, with its lead program targeting thyroid eye disease [11]. Merger Details - The amended agreement allows ACELYRIN stockholders to receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, representing a significant increase in ownership compared to the original merger terms [2]. - The merger is expected to create a leading clinical-stage immunology company with a diversified portfolio of product candidates, enhancing financial flexibility and advancing a late-stage pipeline [5][3]. Financial Position - Alumis reported a pro forma cash position of approximately $737 million as of December 31, 2024, which is expected to support the combined company's pipeline and operational needs into 2027 [5]. - Stockholders representing approximately 62% of Alumis voting common stock and about 24% of ACELYRIN common stock have entered into voting agreements in support of the transaction [6]. Upcoming Events - A Special Meeting of Stockholders for both companies is scheduled for May 13, 2025, where stockholders will vote on the merger [8][7].

Core Points - ACELYRIN, INC. has adopted a limited-duration stockholder rights plan in response to Tang Capital Partners accumulating 8.8% of its outstanding common stock [1][3] - The rights plan aims to maximize stockholder value and is effective immediately, expiring on March 12, 2026 [2][4] Rights Plan Details - Each share of common stock will receive one right, which will become exercisable if any person acquires 10% or more of the company's outstanding common stock [3] - Holders of rights (excluding the acquiring person) can purchase additional shares at a price equal to twice the exercise price [3] - Current owners exceeding the Triggering Percentage can retain their shares but cannot acquire more without triggering the rights plan [3] Company Overview - ACELYRIN focuses on developing transformative medicines in immunology, with its lead program being lonigutamab, a monoclonal antibody for thyroid eye disease [5]